CSTL
Income statement / Annual
Last year (2025), Castle Biosciences Inc's total revenue was $344.23 M,
an increase of 3.66% from the previous year.
In 2025, Castle Biosciences Inc's net income was -$24.16 M.
See Castle Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$344.23 M |
$332.07 M |
$219.79 M |
$137.04 M |
$94.09 M |
$62.65 M |
$51.87 M |
$22.79 M |
$13.75 M |
| Cost of Revenue |
$71.03 M
|
$60.21 M
|
$44.98 M
|
$32.01 M
|
$15.82 M
|
$9.69 M
|
$7.31 M
|
$5.30 M
|
$4.92 M
|
| Gross Profit |
$273.20 M
|
$271.86 M
|
$174.81 M
|
$105.03 M
|
$78.26 M
|
$52.96 M
|
$44.56 M
|
$17.49 M
|
$8.83 M
|
| Gross Profit Ratio |
0.79
|
0.82
|
0.8
|
0.77
|
0.83
|
0.85
|
0.86
|
0.77
|
0.64
|
| Research and Development Expenses |
$51.85 M
|
$52.04 M
|
$53.62 M
|
$44.90 M
|
$29.65 M
|
$13.26 M
|
$7.39 M
|
$4.85 M
|
$4.47 M
|
| General & Administrative Expenses |
$91.21 M
|
$76.58 M
|
$66.50 M
|
$56.40 M
|
$0.00
|
$0.00
|
$0.00
|
$16.47 M
|
$15.26 M
|
| Selling & Marketing Expenses |
$138.12 M
|
$123.47 M
|
$113.66 M
|
$86.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$229.32 M
|
$200.05 M
|
$180.15 M
|
$143.00 M
|
$86.74 M
|
$48.13 M
|
$29.84 M
|
$16.47 M
|
$15.26 M
|
| Other Expenses |
$34.84 M
|
$11.11 M
|
$9.01 M
|
-$10.02 M
|
$1.96 M
|
-$1.88 M
|
$0.00
|
$0.00
|
$163.29 K
|
| Operating Expenses |
$316.01 M
|
$263.19 M
|
$242.78 M
|
$177.89 M
|
$118.34 M
|
$59.51 M
|
$37.23 M
|
$21.32 M
|
$19.73 M
|
| Cost And Expenses |
$387.04 M
|
$323.40 M
|
$287.77 M
|
$209.89 M
|
$134.16 M
|
$69.19 M
|
$44.54 M
|
$26.62 M
|
$24.65 M
|
| Interest Income |
$11.77 M
|
$12.92 M
|
$10.62 M
|
$3.97 M
|
$68.00 K
|
$373.00 K
|
$312.00 K
|
$23.51 K
|
$26.18 K
|
| Interest Expense |
$86.00 K
|
$577.00 K
|
$11.00 K
|
$17.00 K
|
$1.00 K
|
$2.63 M
|
$4.57 M
|
$2.27 M
|
$1.65 M
|
| Depreciation & Amortization |
$40.77 M
|
$16.00 M
|
$12.33 M
|
$10.54 M
|
$3.41 M
|
$472.00 K
|
$358.00 K
|
$323.02 K
|
$310.82 K
|
| EBITDA |
$11.34 M |
$38.14 M |
-$45.02 M |
-$58.34 M |
-$36.60 M |
-$7.09 M |
$10.28 M |
-$3.76 M |
-$10.40 M |
| EBITDA Ratio |
0.03
|
0.11
|
-0.2
|
-0.43
|
-0.39
|
-0.11
|
0.2
|
-0.17
|
-0.76
|
| Operating Income Ratio |
-0.12
|
0.03
|
-0.31
|
-0.53
|
-0.43
|
-0.1
|
0.14
|
-0.17
|
-0.79
|
| Total Other Income/Expenses Net |
$13.30 M
|
$12.89 M
|
$10.61 M
|
$3.95 M
|
$67.00 K
|
-$3.66 M
|
-$1.98 M
|
-$2.52 M
|
-$1.46 M
|
| Income Before Tax |
-$29.51 M
|
$21.56 M
|
-$57.37 M
|
-$68.90 M
|
-$40.01 M
|
-$10.20 M
|
$5.35 M
|
-$6.36 M
|
-$12.36 M
|
| Income Before Tax Ratio |
-0.09
|
0.06
|
-0.26
|
-0.5
|
-0.43
|
-0.16
|
0.1
|
-0.28
|
-0.9
|
| Income Tax Expense |
-$5.36 M
|
$3.32 M
|
$101.00 K
|
-$1.77 M
|
-$8.72 M
|
$84.00 K
|
$72.00 K
|
$8.61 K
|
$9.73 K
|
| Net Income |
-$24.16 M
|
$18.25 M
|
-$57.47 M
|
-$67.14 M
|
-$31.29 M
|
-$10.28 M
|
$5.28 M
|
-$6.37 M
|
-$12.37 M
|
| Net Income Ratio |
-0.07
|
0.05
|
-0.26
|
-0.49
|
-0.33
|
-0.16
|
0.1
|
-0.28
|
-0.9
|
| EPS |
-0.83 |
0.66 |
-2.14 |
-2.58 |
-1.24 |
-0.54 |
0.35 |
-0.6 |
-1.26 |
| EPS Diluted |
-0.83 |
0.62 |
-2.14 |
-2.58 |
-1.24 |
-0.54 |
-0.21 |
-0.6 |
-1.26 |
| Weighted Average Shares Out |
$28.99 M
|
$27.78 M
|
$26.80 M
|
$26.05 M
|
$25.14 M
|
$18.93 M
|
$8.58 M
|
$10.65 M
|
$9.78 M
|
| Weighted Average Shares Out Diluted |
$28.99 M
|
$29.26 M
|
$26.80 M
|
$26.05 M
|
$25.14 M
|
$18.93 M
|
$8.66 M
|
$10.65 M
|
$9.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
